Breast cancer. Agranulocytosis secondary to cancer chemotherapy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Definitive diagnosis of cancer by an oncologist and a pathologist Receiving single-day chemotherapy courses with drugs having high potential for severe nausea, according to the guidelines of the American Society of Clinical Oncology Normal hematological and biochemical test results Informed consent for participation in the study
Exclusion criteria
Exclusion criteria: Simultaneous receipt of radiotherapy with chemotherapy Use of therapeutic doses of warfarin, heparin, or aspirin History of significant bleeding disorders (e.g., severe thrombocytopenia) Diagnosis of gastrointestinal tract cancer or inability to swallow History of ginger or cinnamon allergy, or consumption of these within the past weekPresence of conditions predisposing to nausea, such as uncontrolled hypertension, liver or renal failure, or gastrointestinal disorders Presence of conditions predisposing to nausea, such as uncontrolled hypertension, liver or renal failure, or gastrointestinal disorders Failure to take medications in three or more consecutive instances Use of other medications or therapies to reduce nausea (excluding standard antiemetic and antiemetic drugs prescribed in the study) Development of severe gastrointestinal complications during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nausea-vomiting. Timepoint: Over three sessions (day 1, day 2, and day 3). Method of measurement: nausea and vomiting will be assessed using the INVR questionnaire (The Index of Nausea, Vomiting, and Retching). | — |
Countries
Iran (Islamic Republic of)
Contacts
Jahrom University of Medical Sciences